Hydroxyethyl starch 130/0.4: Safe for the kidney in surgical patients?

Anesthesiology

Volumn 119, Issue 3, 2013, Pages 735-736

  Wiedermann, Christian J ^a  

^a CENTRAL HOSPITAL OF BOLZANO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HETASTARCH;

ACUTE KIDNEY FAILURE; BLEEDING; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; ERYTHROCYTE TRANSFUSION; HEART SURGERY; HUMAN; KIDNEY; KIDNEY FAILURE; KIDNEY INJURY; LETTER; META ANALYSIS (TOPIC); MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; SAFETY; SEPSIS; SURGICAL PATIENT;

HETASTARCH; HUMANS; KIDNEY; KIDNEY DISEASES; PLASMA SUBSTITUTES; ZEA MAYS;

EID: 84883231632     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e31829ff30f     Document Type: Letter

References (13)

1. Wiedermann CJ: Hydroxyethyl starch-Can the safety problems be ignored? Wien Klin Wochenschr 2004; 116: 583-94 (Pubitemid 39349828)
2. Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, Fergusson DA: Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: A systematic review and meta-analysis. JAMA 2013; 309: 678-88
3. Perel P, Roberts I, Ker K: Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev 2013; 2:CD000567
4. Wiedermann CJ, Joannidis M: Increased mortality after infusion of "modern" hydroxyethyl starch. Swiss Med Wkly 2013; 143:w13747
5. G attas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S; CHE ST Management Committee: Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: Systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med 2013; 39: 558-68
6. H aase N, Perner A, Hennings LI , Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J: Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: Systematic review with meta-analysis and trial sequential analysis. BMJ 2013; 346:f839
7. Patel A, Waheed U, Brett SJ: Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: Systematic review and meta-analysis. Intensive Care Med 2013; 39: 811-22
8. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, Madsen KR, Møller MH, Elkjær JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Søe-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH , Holst LB, Thormar K, Kjældgaard A-L, Fabritius ML, Mondrup F, Pott FC, Møller TP, Winkel P, Wetterslev J: Hydroxyethyl starch 130/0.4 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; 367: 124-34
9. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb SA, Beale RJ, Vincent JL, Moreno R; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41: 580-37
10. Martin C, Jacob M, Vicaut E, Guidet B, Van Aken H, Kurz A: Effect of waxy maize-derived hydroxyethyl starch 130/0.4 on renal function in surgical patients. Anesthesiology 2013; 118: 387-94
11. Wilkes MM, Navickis RJ: Patient survival after human albumin administration. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 135: 149-64 (Pubitemid 32738309)
12. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L: Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: A multicentre randomised study. Lancet 2001; 357: 911-6 (Pubitemid 32247279)
13. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P: Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996; 348: 1620-2 (Pubitemid 27007061)